- Home
- SRFM vs CANF Comparison
SRFM vs CANF Comparison
Compare SRFM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- CANF
- Stock Information
- Founded
- SRFM 2011
- CANF 1994
- Country
- SRFM United States
- CANF Israel
- Employees
- SRFM N/A
- CANF N/A
- Industry
- SRFM Transportation Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- CANF Health Care
- Exchange
- SRFM Nasdaq
- CANF Nasdaq
- Market Cap
- SRFM 62.8M
- CANF 14.4M
- IPO Year
- SRFM 2023
- CANF N/A
- Fundamental
- Price
- SRFM $3.33
- CANF $1.48
- Analyst Decision
- SRFM Hold
- CANF Strong Buy
- Analyst Count
- SRFM 2
- CANF 2
- Target Price
- SRFM $3.40
- CANF $14.00
- AVG Volume (30 Days)
- SRFM 607.1K
- CANF 1.2M
- Earning Date
- SRFM 11-14-2024
- CANF 12-31-2024
- Dividend Yield
- SRFM N/A
- CANF N/A
- EPS Growth
- SRFM N/A
- CANF N/A
- EPS
- SRFM N/A
- CANF N/A
- Revenue
- SRFM $118,212,000.00
- CANF $667,000.00
- Revenue This Year
- SRFM $102.41
- CANF $409.56
- Revenue Next Year
- SRFM $47.46
- CANF N/A
- P/E Ratio
- SRFM N/A
- CANF N/A
- Revenue Growth
- SRFM 198.78
- CANF N/A
- 52 Week Low
- SRFM $0.90
- CANF $1.29
- 52 Week High
- SRFM $11.83
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SRFM 50.96
- CANF 35.58
- Support Level
- SRFM $2.76
- CANF $1.30
- Resistance Level
- SRFM $4.50
- CANF $1.72
- Average True Range (ATR)
- SRFM 0.81
- CANF 0.18
- MACD
- SRFM -0.18
- CANF -0.01
- Stochastic Oscillator
- SRFM 20.92
- CANF 17.92
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).